Clinical characterization of arrhythmia-induced tachymyopathy (AIC)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017515

Enrollment

Registered

2019-09-30

Start date

2018-08-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I42.9 I50.1

Interventions

Group 1: Patients with suspicion of an arrhythmia-induced cardiomyopathy (AIC) undergo the following diagnostic tests within the initial hospital stay: ECG (for rhythm evaluation), blood sample (inter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suptraventricular tachycardia (100/min), unexplained left ventricular systolic dysfunction (LVEF 18y, informed consent.

Exclusion criteria

Exclusion criteria: History of previous significant non AIC-LVSD (EF<50%), myocardial infarction within the last 3 months. Long persistent or permanent AF.

Design outcomes

Primary

Measure	Time frame
The dual primary end point ‘prevalence of arrhythmia-indced cardiomyopathy and time to recovery of systolic heart function” is determined after the outpatient visit at six months. The prevalence of AIC is calculated by the quotient from the number of patients in arm 1 and the total number of patients. For the classification in the specific study arm, LVEF is used, which is measured by echocardiography.	—

Measure

Time frame

The dual primary end point ‘prevalence of arrhythmia-indced cardiomyopathy and time to recovery of systolic heart function” is determined after the outpatient visit at six months. The prevalence of AIC is calculated by the quotient from the number of patients in arm 1 and the total number of patients. For the classification in the specific study arm, LVEF is used, which is measured by echocardiography.

—

Secondary

Measure	Time frame
Parameters to differentiate between AIC and non-AIC: cMRI detected fibrosis (late gadolinium enhancement, LGE) including LGE positive vs. negative LGE, and inverse correlation % LGE, and change LVEF (echocardiography). LV end-diastolic and end-systolic diameter (echocardiography). Left atrial (LA) dimension (echocardiography). Serum concentrations of N-terminal pro-BNP (NT-proBNP) and Troponin. Symptoms of arrhythmia, NYHA Classification, type of arrhythmia, heart rate (ECG), and age. Prevalence of AIC: Mitral insufficiency, specific antiarrhythmic therapy applied, hospitalization for heart failure/arrhythmia/cardiovascular, quality of life, AIC recurrence, overall survival, cardiovascular (CV) mortality, sudden cardiac death (SCD), symptoms of arrhythmia, NYHA Classification, type of arrhythmia, and demographic and clinical variables. These parameters are collected at the initial hospital stay. In the outpatient visits two, four and six months after that, these parameters were measured again except for the cMRI-data.	—

Measure

Time frame

Parameters to differentiate between AIC and non-AIC: cMRI detected fibrosis (late gadolinium enhancement, LGE) including LGE positive vs. negative LGE, and inverse correlation % LGE, and change LVEF (echocardiography). LV end-diastolic and end-systolic diameter (echocardiography). Left atrial (LA) dimension (echocardiography). Serum concentrations of N-terminal pro-BNP (NT-proBNP) and Troponin. Symptoms of arrhythmia, NYHA Classification, type of arrhythmia, heart rate (ECG), and age. Prevalence of AIC: Mitral insufficiency, specific antiarrhythmic therapy applied, hospitalization for heart failure/arrhythmia/cardiovascular, quality of life, AIC recurrence, overall survival, cardiovascular (CV) mortality, sudden cardiac death (SCD), symptoms of arrhythmia, NYHA Classification, type of arrhythmia, and demographic and clinical variables. These parameters are collected at the initial hospital stay. In the outpatient visits two, four and six months after that, these parameters were measured again except for the cMRI-data.

—

Countries

Germany

Contacts

Public ContactChristian Schach

Universitäres Herzzentrum Regensburg, Innere Medizin 2, Abteilung für Kardiologie

christian.schach@ukr.de0049 (0)941 944-7268

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026